Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC.
“This live demonstration presented a case of a 51 year-old diabetic patient with complex multi-vessel disease involving a long fibrotic lesion. Elixir’s DESolve NXT Plus had excellent visibility, smooth deliverability and DES-like inflation that enabled me to treat the diseased artery with ease and confidence,” said Dr. Stefan Verheye, M.D., Ph.D., ZNA Middleheim, Antwerp, Belgium, who performed the procedure with the DESolve NXT Plus in his cardiac catheterization lab in Belgium from where it was streamed live to a packed audience in the Main Arena of the Washington Convention Center at TCT. “I’m pleased to report that the acute outcome of the procedure was successful, and the patient is doing well.”
The DESolve NXT Plus is a third-generation bioresorbable scaffold system from Elixir Medical. The scaffold’s 120 µm struts are contoured for enhanced acute performance with improved force transmission allowing it to embed better into the vessel and improve lesion expansion. Additionally, the DESolve NXT Plus introduces the unique TRANSFORM™ Balloon Technology designed to enhance scaffold expansion in the most resistant segment of the lesion, minimize edge dissection during deployment and improve concentric expansion.
Typically scaffold struts are rectangular, which are hypothesized to lead to a “snow-shoe” effect of sub-optimal embedding and implantation. The improved force transmission of the DESolve NXT’s contoured struts is intended to minimize the snow-shoe effect and improve force transmission to the lesion, potentially making it the most advanced scaffold. In addition, Elixir’s NXT system continues to leverage the CE Mark-approved DESolve® polymer technology designed to allow for early 6-month vessel uncaging, degradation within one year, and returning the patients’ coronary vessel ultimately to its normal de novo state.
“The successful live case demonstration of Elixir’s DESolve NXT Plus System at TCT reinforces our commitment to providing cardiologists with state-of-the-art bioresorbable scaffold products that match the excellent deliverability and enhanced conformability of market-leading coronary drug eluting stents to ensure their greater adoption in everyday clinical practice,” said Motasim Sirhan, Chief Executive Officer of Elixir Medical. “Moreover, Elixir will be able to leverage the novel TRANSFORM Balloon Technology across all our scaffold platforms making Elixir’s bioresorbable scaffold portfolio the broadest and most innovative in the world.”
Similar to the CE Marked and clinically-proven DESolve scaffold, DESolve NXT Plus is developed from the same proprietary poly-L Lactide (PLLA)-based material that provides optimal strength and support to the artery while delivering the novel anti-proliferative drug, Novolimus. The unique attributes of the DESolve family of scaffolds include fracture- resistance, the ability to provide vessel support for the necessary period of vessel healing, and uncaging the vessel within six months.
ABOUT ELIXIR MEDICAL
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company’s next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com.